Journal: bioRxiv

Article Title: hiPSC-CM Electrophysiology: Impact of Temporal Changes and Study Parameters on Experimental Reproducibility

doi: 10.1101/2023.10.02.560475

Figure Lengend Snippet: hiPSC-CM electrophysiology data was collected (4 vs 10 days post-defrost) at baseline and after exposure to a hERG channel blocker (E-4031), calcium channel blocker (nifedipine), or beta-adrenergic agonist (isoproterenol). A) Percent change in the spontaneous beating rate, normalized to baseline measurement (repeated-measures) after 15-minute drug treatment. B) Representative traces of spontaneous beating after drug treatment. C-E) Percent change in the field potential duration, spike amplitude, and conduction velocity (normalized to baseline measurement) after 15-minute drug treatment. hiPSC-CMs were externally paced to normalize the beating rate (1.5 Hz for E-4031 which slowed the intrinsic rate; 3 Hz for nifedipine and isoproterenol which increased the intrinsic rate). F-H) Percent change in the action potential duration at 30%, 50%, and 90% repolarization (normalized to baseline measurement) after 15-minute drug treatment. hiPSC-CMs were externally paced to normalize the beating rate (1.5 Hz for E-4031; 2 Hz for nifedipine and isoproterenol). Measurements are shown as a Tukey box-and-whisker plot. Unpaired Student’s t-test, two tailed. *p<0.05, **p<0.01, ****p<0.0001. Number of replicates indicated.

Article Snippet: A hERG channel blocker (50 nM E-4031, #15203 Cayman Chemical) was tested for its ability to prolong FPD and APD( , , ).

Techniques: Whisker Assay, Two Tailed Test

Journal: Cells

Article Title: hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us

doi: 10.3390/cells8111331

Figure Lengend Snippet: MEA based safety testing of drugs without cardiac indication using human induced pluripotent stem cell cardiomyocyte (hiPSC-CM).

Article Snippet: Alfuzosin , Treatment of benign prostatic enlargement, a hERG-channel blocker , Clinical QT prolongation , 30 nM , hiPSC-CM iCell™ (mixture of ventricular, atrial, nodal cells) , n/a , 32 days of differentiation +15–26 days , MEA , [ , ] .

Techniques: Blocking Assay, Activity Assay, Patch Clamp, Derivative Assay

Journal: Cells

Article Title: hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us

doi: 10.3390/cells8111331

Figure Lengend Snippet: MEA based safety testing of drugs with cardiac indication using hiPSC-CM.

Article Snippet: Alfuzosin , Treatment of benign prostatic enlargement, a hERG-channel blocker , Clinical QT prolongation , 30 nM , hiPSC-CM iCell™ (mixture of ventricular, atrial, nodal cells) , n/a , 32 days of differentiation +15–26 days , MEA , [ , ] .

Techniques: Blocking Assay, Patch Clamp, Microelectrode Array